Skip to Content
Get key facts and figures about chronic dry eye

Aflibercept ophthalmic Pregnancy and Breastfeeding Warnings

Aflibercept ophthalmic is also known as: Eylea

Medically reviewed on August 1, 2017

Aflibercept ophthalmic Pregnancy Warnings

Animal studies have revealed evidence of embryofetal toxicity. There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: D
US FDA pregnancy category: C

Comments:
-Women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last injection.

See references

Aflibercept ophthalmic Breastfeeding Warnings

Use is not recommended. A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.

References for breastfeeding information

  1. "Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide